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CD4+ T cell mediated uveitis is conventionally treated with systemic immunosuppressive
agents, including corticosteroids and biologics targeting key inflammatory cytokines.
However, their long-term utility is limited due to various side effects. Here, we investigated
whether DNA methylation inhibitor zebularine can target CD4+ T cells and control
intraocular inflammation. Our results showed that zebularine restrained the expression
of inflammatory cytokines IFN-γ and IL-17 in both human and murine CD4+ T cells
in vitro. Importantly, it also significantly alleviated intraocular inflammation and retinal
tissue damage in the murine experimental autoimmune uveitis (EAU) model in vivo,
suggesting that the DNA methylation inhibitor zebularine is a candidate new therapeutic
agent for uveitis.
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INTRODUCTION
Autoimmune uveitis is a heterogeneous collection of diseases characterized by intraocular
inflammation (1). Affected patients are at risk of visual impairment or blindness (2), in
particular those who are resistant or intolerant to conventional immunosuppressive therapies
(3–5). Consequently there is a need to develop improved approaches to achieve control of
intraocular inflammation.
Abnormal activation of the T helper (Th) cells and imbalance between inflammatory Th1/Th17
and regulatory T (Treg) cells play a key role in the pathogenesis of autoimmune uveitis (6–8).
Modulating Th cell differentiation and function has been proposed as a therapeutic strategy
for uveitis (9). The expression of signature cytokines and master transcription factors, as well
as Th functions, are under tight control of coordinated epigenetic alterations (10, 11). And
many genome-wide and locus-specific epigenetic changes have been found in patients with
immune-mediated diseases such as systemic lupus erythematosus and rheumatoid arthritis (12).
Therefore, modulating the epigenetic program that controls Th1, Th17, and Treg functions may
serve as a new way to control the intraocular inflammation in uveitis.
Two key epigenetic mechanisms—DNA methylation and histone modifications—regulate
chromatin accessibility, and have been the targets of a series of compounds developed in
recent years for the treatment of cancers and immune-mediated diseases (12). Among these
small-molecule inhibitors, twoDNAmethyltransferase (DNMT) inhibitor pro-drugs, 5-azacytidine
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and 2′-deoxy-5-azacytidine have been approved for the treatment
of myelodysplastic syndrome and acute myeloid leukemia (13).
In addition, an anti-inflammatory effect of these two drugs
has also been observed in murine models of asthma (14) and
experimental autoimmune encephalomyelitis (15). We therefore
hypothesize that another DNAmethylation inhibitor, zebularine,
which has relatively low cellular toxicity and a longer half-life
(16), has the potential to suppress uveitis.
Here, to elucidate whether zebularine is able to control
the intraocular inflammation through regulating the expression
of inflammatory cytokines in CD4+ T cells, we explored
the changes of IFN-γ, IL-17, and Foxp3 (17) in response
to zebularine treatment in Th1, Th17, and Treg cells. In
addition, the immunosuppressive effects of zebularine in vivo
were also evaluated using the murine experimental autoimmune
uveitis model.
MATERIALS AND METHODS
Human Peripheral Blood CD4+ T Cell
Isolation
CD4+ T cells were obtained by negative selection from peripheral
blood of healthy controls (HCs) (N = 4; 3 female and 1 male;
average age of 42) following informed consent in accordance with
National Health Service Research Ethic Committee approved
protocols at the University Hospitals Bristol Foundation Trust,
United Kingdom (04/Q2002/84). Written, informed consent
was obtained from all study participants. CD4+ T cells were
obtained by incubating up to 80ml uncoagulated peripheral
blood with RosetteSepTM Human CD4+ T cell Enrichment
Cocktail (Stemcell Technologies, Canada) according to the
manufacturer’s instructions. Blood was then layered on Ficoll-
Paque PLUS (GE Healthcare, USA) and centrifuged for 1,200
× g for 20min. Enriched CD4+ T cells were removed from
the density gradient and washed in RPMI-1640 (Thermofisher)
supplemented with 10% fetal calf serum (FCS). The purity of
human CD4+ T cells was>95%.
Mice
Female C57BL/6 2-Hb mice (8–10 weeks) were purchased
from Guangdong Medical Laboratory Animal Center (China)
and maintained in a SPF facility in Zhongshan Ophthalmic
Center of Sun Yat-sen University. All animal experiments were
approved by the Institutional Animal Care andUse Committee of
Zhongshan Ophthalmic Center. All animal work was performed
in compliance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
Antibodies and Reagents
Zebularine was purchased from Tocris Bioscience (UK).
The recombinant mouse interleukin-6 (rmIL-6), rmIL-12,
recombinant human transforming growth factor beta 1 (rhTGF-
β1) were purchased from R&D Systems (USA). Functional
antibodies anti-CD3 (145-2C11) and anti-CD28 (37.51), FACS
antibodies anti-IL-17A (eBio17B7), anti-IFN-γ (XMG1.2) and
anti-Foxp3 (FJK-16s) were from eBioscience (USA). CD4 (L3T4)
and naïve CD4+ T cell Magnetic-activated cell sorting (MACS)
isolation kits were purchased from Miltenyi (Germany). The
complete Freund’s adjuvant and pertussis toxin were purchased
from Sigma-Aldrich (USA).
Cell Culture
Human peripheral CD4+CCR6− and CD4+CCR6+ cells (N =
4; 3 female and 1 male; average age of 42) were FACS-sorted
from isolated CD4+ T cells, resuspended to 2 × 106 cells/mL
in RPMI-1640 supplemented with 10% FCS, L-glutamine, and
penicillin/streptomycin (all Thermofisher, stimulated with plate-
bound anti-CD3 (5µg/mL; clone UCHT1) and anti-CD28
(5µg/mL;clone CD28.2) antibodies (eBioscience) (CCR6− cells)
or with plate-bound antibodies and a polarizing cytokine
mixture of 20 ng/mL IL-6, 10 ng/mL IL-23, 10 ng/mL IL-1β (all
from R&D Systems), 100 ng/mL anti-IFN-γ, 100 ng/mL anti-
IL-4 (eBioscience) (CCR6+ cells) for 5 days. Zebularine was
also added at the indicated concentrations at the beginning of
cultures. For murine CD4+ T cells, spleen and lymph node
cells were filtered through a 40-µm cell strainer, followed by
the red blood cell lysis using ammonium-chloride-potassium
(ACK) buffer. Total CD4+ T cells were then isolated with
the CD4 (L3T4) T cell isolation kit using the autoMACS Pro
Separator (Miltenyi, Germany) and stimulated by plate-bound
of anti-CD3 (5µg/mL) and anti-CD28 (2µg/mL) antibodies, as
well as mIL-12 10 ng/mL, mIL-2 10 ng/mL, anti-IL-4 10µg/mL
(Th1); mIL-6 20 ng/mL, rhTGF-β1 1 ng/mL, anti-IL-4 10µg/mL,
anti-IFN-γ 10µg/mL (Th17); and mIL-2 50 ng/mL, rhTGF-
β1 2 ng/mL (Treg) for 3 days. When zebularine was used,
the indicated doses of drug were added at the beginning of
the culture.
RNA-seq Analysis
Total RNA from Th1, Th17, and Treg cells was extracted
with the MasterPure Complete DNA and RNA Purification Kit
(Epicentre, UK) according to the manufacture’s instruction. A
total of 100 ng RNA was sonicated into fragments of 300–400
base pairs using Bioruptor (Diagenode, Belgium). mRNA library
was prepared using VAHTS mRNA-seq V3 Library Prep Kit for
Illumina (Vazyme, Nanjing, China) following the manufacture’s
protocol and sequenced on the Illumina HiSeq2500 sequencer
with HiSeq SR Cluster Kit V4 and HiSeq SBS Kit V4 50 cycle
kit (Illumina). The initial processing was performed by CASAVA
(v1.8.2). Sequencing reads were then subjected to quality control
processed by FastQC (v0.11.5) and trimmed by Cutadapt (v1.9.1).
Quality controlled reads were then analyzed using DEseq2.
Quantitative Real-Time PCR (qPCR)
Total RNA from T cells was extracted with the MasterPure
Complete DNA and RNA Purification Kit (Epicentre, UK),
and cDNA was synthesized with the PrimeScriptTM cDNA
Synthesis Kit (Takara, Japan). qRT-PCR was performed using
SYBR Green PCR Master Mix (KAPA Biosystems, USA) on
the Light Cycler 480 instrument (Roche, Switzerland). The
samples were run in duplicate and the relative expression
was determined by normalizing the expression of each gene
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using
the 2−11Ct method. The primers used are shown in the
Supplementary Table 1.
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Drug Treatment in Mice
Zebularine was reconstituted with 0.9% saline to make a 1 µg/µL
stock and stored at −80◦C. Zebularine was administered to the
mice at 10µg/g body weight by intraperitoneal injection. The
injection was started on day 7 post-immunization and performed
daily for 7 consecutive days. The control group was injected with
0.9% saline only. Body weights of both groups were monitored
after drug treatment.
EAU Induction and Scoring
C57BL/6 mice were immunized subcutaneously, at the base
of tail (100 µL) and in both thighs (50 µL), with total 50
µg human interphotoreceptor retinoid binding (IRBP) 651−670
emulsified with complete Freund’s adjuvant supplemented with
3.5mg Mycobacterium tuberculosis. Each mouse also received
1 µg pertussis toxin (Tocris Bioscience, UK) intraperitoneally.
To assess the clinical score of EAU, we performed dilated-pupil
FIGURE 1 | The expression of IFN-γ and IL-17A in zebularine-treated human CD4+ T cells in vitro. (A) Representative dot plots (N = 4; 3 female and 1 male; average
age of 42) for stimulated human CD4+CCR6− and CD4+CCR6+ cells on Day 5, stained with IFN-γ and IL-17A. The frequency of CD4+ IFN-γ+ IL-17− (B),
CD4+ IFN-γ− IL-17+ (C), and CD4+ IFN-γ+ IL-17+ (D) Cells in zebularine-treated human CD4+CCR6+ and CD4+CCR6− cells. (E) Viability of CD4+CCR6− and
CD4+CCR6+ cells treated with different doses of zebularine. Means ± SD are shown.
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fundus examination with a Micron III murine fundus camera
(Phoenix Research Labs, USA) and histological assessment of
FFPE sections of the retinal tissues from EAU mice (18). The
clinical scores were given by two independent experienced
observers in a blindfold manner based on the criteria for EAU
scoring as described previously (19).
Flow Cytometry and FACS Sorting
For FACS-sorted human cells, pre-enriched CD4+ T cells were
incubated with a combination of primary antibodies against
cell surface markers at 4◦C for 30min and then washed using
PBS (v/v 10% FCS and 1mM EDTA). Antibodies used for
human CCR6T cell FACS sorts were anti-CD4 AF700 (BD
Biosciences), anti-CD3 BV510 (BD Biosciences) and CCR6
PE (BD Biosciences). 7-AAD (Biolegend, USA) was used to
discriminate living cells. Cells were sorted into CD4+CCR6− and
CD4+CCR6+ subsets using a BD Influx (BD Biosciences) and
routinely >95% purity was achieved. Both human and murine
cultured or single cell suspensions collected from human CCR6
5-day cultures and retina, spleen, or lymph nodes from mice
were stimulated with 20 ng/ml phorbol myristate acetate (PMA),
1 µM ionomycin (Sigma-Aldrich, USA) and 1 µl/ml GolgiStop
(BD Biosciences) for 4 h at 37◦C. After 4 h, cells were washed
with PBS (v/v 10% FCS and 1mM EDTA), stained with Infrared
Live/Dead fixable dye (ThermoFisher) fixed and permeabilized
(Cytofix/perm solution; BD Biosciences) and stained with anti-
IL-17A, anti-IFN-γ, and anti-Foxp3 antibodies. Samples were
acquired using a BD LSRFortessaTM X-20 (BD Biosciences).
Results were analyzed using Flowjo v10 (Treestar).
Bisulfite Sequencing
Total DNA isolated from mouse polarized Treg cells was
extracted with the MasterPure Complete DNA and RNA
Purification Kit (Epicentre, UK). Sodium bisulfite treatment of
total DNA was performed using the EZ DNA Methylation-
Gold Kit (Zymo Research, USA) according to the manufacturer’s
instruction. PCR amplification was performed on the T100
Thermal Cycler (Bio-Rad, USA) in a final volume of 50 µL. PCR
products were purified with the Zymoclean Gel DNA Recovery
Kit (Zymo Research, USA). The sequencing results were analyzed
by BiQ Analyzer (Max Planck Institut Informatik, Germany).
The following primers pairs were used: Foxp3 enhancer CpG
FIGURE 2 | The expression of IFN-γ and IL-17A in zebularine-treated murine Th1 and Th17 cells in vitro. (A) Representative dot plots (N = 5) for murine Th1 and
Th17 cells stained with IFN-γ and IL-17A. (B) The percentages of IFN-γ+ and IL-17+ cells in zebularine-treated murine CD4+ T cells. (C) Viability of murine Th1 and
Th17 cells treated with different doses of zebularine. Means ± SD are shown.
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FIGURE 3 | Genome-wide expression profiles of Th1, Th17, and Treg cells in response to zebularine stimulation. (A) Principle component analysis of genes with at
least two-fold changes between any two conditions and P < 0.05 (one-way ANOVA). -Z represents the conditions with zebularine stimulation. (B) Hierarchical
clustering analysis of Th1, Th17, and Treg cells with (-Z) or without zebularine stimulation. (C) Hierarchical clustering of genes of interest in Th1, Th17, and Treg cells.
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FIGURE 4 | The relative RNA expression of Ifng (A) and Tbx21 (C) in murine Th1 cells, Il17a (B) and Rorc (D) in murine Th17 cells. RNA was extracted from murine
CD4+ T cell subsets polarized for 3 days with or without zebularine and evaluated by qRT-PCR. N = 5, *P < 0.05.
island (−5782 to−5558): (F: AATG TGGG TATT AGGT AAAA
TTTT T; R: AAAC CCTA AAAC TACC TCTA AC), Foxp3
promoter CpG island (−5252 to−5030): (F: TAGGTGAT TGAT
AAGT AGGA GAAG TTAG TA; R: TACC CCCA TTAC TTAT
AACC ATTTC).
Statistical Analysis
Statistical analysis was performed with Prism Graphpad 7.0
(GraphPad Software, USA). Mann-Whitney U test or one-way
ANOVA test was used accordingly.
RESULTS
Zebularine Restrains the Expression of
IFN-γ and IL-17A in CD4+ T Cells in vitro
To assess the effects of zebularine on the expression of
proinflammatory cytokines, we first examined the human
peripheral CD4+ T cells. FACS-sorted CD4+CCR6− and
CD4+CCR6+ cells were stimulated with anti-CD3/anti-CD28
antibodies or under the Th17 polarizing condition, respectively.
As shown in Figure 1, the frequency of IFN-γ+IL-17− cells
was significantly reduced in both CCR6+ and CCR6− cells in
response to zebularine treatment (Figures 1A,B), while IL-17
expression was restrained by zebularine in a dose dependent
manner (Figures 1A,C,D). The viability of CD4+ T cells was not
significantly affected by zebularine treatment (Figure 1E). These
data suggest that zebularine is able to control the inflammatory
cytokine expression in human CD4+ T cells.
To further explore the immunomodulatory effect of
zebularine in murine cells, we differentiated murine peripheral
CD4+ T cells into inflammatory Th1 and Th17 conditions.
Similar to the findings in human CD4+ T cells, zebularine
was found to significantly suppress the protein expression
of IFN-γ and IL-17A (Figures 2A,B) in murine Th1 and
Th17 cells, respectively. However, the cell viability was
significantly compromised in response to those high dose
zebularine treatments (Figure 2C). To confirm the global
changes zebularine stimulation may lead to on CD4+ T cells,
we performed genome-wide expression analysis of murine Th1
and Th17 cells in response to zebularine stimulation using
the mRNA-seq technology. The principal component analysis
(Figure 3A) and hierarchical clustering analysis (Figure 3B) of
all of the differentially expressed genes (defined as a two-fold
change between any two conditions, with a one-way ANOVA
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FIGURE 5 | Zebularine promotes the expression of Foxp3 in murine CD4+ T cells in vitro. (A–C) The relative RNA expression of Foxp3 in zebularine-treated murine
Th1, Th17 and Treg cells *P < 0.05; **P < 0.01. (D) Representative dot plots (N = 5) for murine Treg cells stained with IFN-γ and Foxp3. (E) The percentages of
Foxp3+ cells in zebularine-treated murine CD4+ T cells. Means ± SD are shown. (F) Viability of murine Treg cells treated with different doses of zebularine. Means ±
SD are shown. (G) Methylation status of the CpG islands located in Foxp3 enhancer in murine Treg cells treated with zebularine or vehicle. •, methylated CpG; ◦,
unmethylated CpG.
P < 0.05) revealed that zebularine significantly changed global
gene expression profiles of Th1 and Th17 cells, in addition to
the significant modulation of Il17a expression in Th17 cells
(Figure 3C). We next performed quantitative PCR analysis to
confirm the changes of mRNA expression of the inflammatory
cytokines and key transcription factor Tbx21, which encodes
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FIGURE 6 | The intraocular inflammation of EAU mice was attenuated by zebularine treatment in vivo. The representative fundus images (A) and fundus scores (B)
(means ± SD) of EAU mice treated with zebularine (N = 10) or vehicle (N = 10) were shown ****P < 0.0001. (C) Body weights of EAU mice (means ± SD) treated with
zebularine (N = 10) or vehicle (N = 10) were monitored every day during treatment and every week after treatment.
the Th1 master regulator Tbet found by RNA-seq analysis. The
expression of Ifng (Figure 4A), Tbx21 (Figure 4C), and Il17a
(Figure 4B) was significantly decreased by zebularine in Th1
and Th17 cells, respectively, while the relative RNA expression
of Rorc was increased in Th17 cells in response to zebularine
treatment (Figure 4D). Taken together, our data demonstrated
the immunomodulatory function of zebularine on both human
and murine CD4+ T cells in vitro.
Zebularine Promotes the Expression of
Foxp3 in Murine CD4+ T Cells in vitro
In addition to the effects on cytokine expression, we also
investigated whether zebularine modulated the expression of
Foxp3, the key transcription factor controlling the development
and function of Treg (20). The genome-wide expression
analysis demonstrated a significant response of Treg cells
to the zebularine stimulation (Figures 3A,B). As shown in
Figures 3C, 5A,B, the RNA expression of Foxp3 was activated
and significantly increased in response to the treatment of
zebularine in Th1 and Th17 cells. Under inducible Treg
polarizing condition, high dose of zebularine was not able to
further elevate the expression of Foxp3 (Figures 5C–E). It is
noteworthy that zebularine treatment at 10µg/mL significantly
decreased the viability of Th1 cells (Figure 2C), while the Treg
cells were still highly viable (Figure 5F). These data suggest that
zebularine promotes the expression of Foxp3 in CD4+ T cells.
The epigenetic regulation of Foxp3 expression by DNA
methylation alterations was well documented by previous studies
(21). Therefore, we next assessed whether the methylation status
of the CpG islands located in Foxp3 enhancer was changed by
zebularine in Treg cells, using the bisulfite sequencing technique.
As shown in Figure 5G, the Foxp3 upstream enhancer (−5786 to
−5558) was hypermethylated in the vehicle-treated control cells
(66% methylated), while all 23 CpG islands were demethylated
in cells treated with zebularine (10µg/mL). These data further
demonstrate that zebularine promotes the expression of Foxp3 in
CD4+ T cells through demethylating its enhancer region.
Zebularine Controls Intraocular
Inflammation in vivo
To investigate the anti-inflammatory effect of zebularine in vivo,
we treated EAU mice intraperitoneally with zebularine and
investigated the changes of intraocular inflammation. Fundus
examination was performed every 7 days to evaluate the
severity of intraocular inflammation in EAU mice. As shown
in Figures 6A,B, the retinal tissue damage started on Day 7
and peaked at Day 14 post immunization. However, zebularine
treatment significantly reduced the severity of intraocular
inflammation and retinal tissue damage, evidenced by the fundus
clinical score reduction from 2.91 ± 0.24 (vehicle treated group)
to 0.88± 0.16 (zebularine treated group) on Day 14. Importantly,
during the 5 weeks when mice received zebularine treatment,
we did not observe any body weight changes (Figure 6C).
Consistent with the fundus examination result, histological
analyses of the retinal tissues from EAUmice on the disease peak
Day 14 post immunization revealed that zebularine treatment
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FIGURE 7 | Histological analyses of the retinal tissues from EAU mice treated with zebularine or vehicle on Day 14 post immunization. (A) Representative HE
histological sections of EAU mice treated with zebularine or vehicle. The fundus scores and histology scores of EAU mice treated with zebularine (N = 16) or vehicle
(N = 15) on Day 14 are shown in (B,C). Means ± SD are shown ****P < 0.0001.
significantly alleviated intraocular inflammation and retinal
tissue damage (Figures 7A–C). Taken together, our data suggest
that zebularine significantly reduces intraocular inflammation
and retinal damage in vivo.
Since zebularine restrained inflammatory cytokine expression
in CD4+ T cells in vitro, we next prepared single cell
suspensions from the eyes, cervical lymph nodes (CLN),
peripheral lymph nodes (PLN) and spleen of EAU mice treated
with or without zebularine on Day 14 post-immunization
and analyzed the changes of IFN-γ, IL-17, and Foxp3
expression. As shown in Figures 8A–E, the frequency of both
intraocular CD4+IFN-γ+ and CD4+IL-17+ cells was reduced
by zebularine, while the frequency of CD4+Foxp3+ cells
was elevated (Figures 8B,F). In contrast, the expression of
IFN-γ, IL-17, and Foxp3 was not significantly changed in
CLN, PLN, and spleen (Figures 8A–F). Therefore, these data
further demonstrate that zebularine controls ocular specific
inflammation without significantly altering the systemic CD4+
T cell populations.
DISCUSSION
CD4+ T cells mediate systemic and local inflammation in uveitis
(22). Our current study suggests that the DNA methylation
inhibitor zebularine suppresses the expression of inflammatory
cytokines IFN-γ and IL-17 in CD4+ T cells in vitro and in
vivo, promotes Foxp3 expression, and alleviates the severity of
intraocular inflammation and retinal tissue damage in EAUmice.
To our knowledge, this is the first report showing that zebularine
is a potential therapeutic agent for uveitis.
Previous studies have demonstrated the clinical utility of DNA
methylation inhibitors in oncology, especially in the treatment
of myelodysplastic syndrome and acute myeloid leukemia (12).
However, it is only recently that these drugs have been evaluated
in the context of experimental models of inflammatory disease
(14, 15, 23–27). This showed that systemic administration of
the two DNA methylation inhibitors azacytidine and decitabine
for treating immune-mediated diseases was limited due to
their significant cytotoxicity and side-effects (28). In contrast,
our data revealed limited cytotoxicity of zebularine on human
CD4+ T cells in vitro and limited systemic toxicity of
zebularine in mice in vivo, suggesting that zebularine may
be a better immunosuppressive agent in comparison to the
other DNA methylation inhibitors. Importantly, several reports
have identified indoleamine 2,3-dioxygenase (IDO) as the
targets of zebularine through which zebularine carried out
immunomodulatory functions on cancer and autoimmunity
treatments (29–31). Our data on CD4+ T cells provided
another possible mechanism by which zebularine carried out its
immunosuppressive function.
Tbet, RORγt, and Foxp3 are the canonical transcription
factors promoting Th1, Th17, and Treg polarization (11). We
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FIGURE 8 | Analysis of CD4+ T cells in inflamed eyes, as well as lymph nodes. (A,B) The representative FACS analysis of the frequency of IFN-γ+, IL-17+, and
Foxp3+ cells in single cell suspensions (pooled from 5 mice) prepared from the eyes, cervical lymph nodes (CLN), peripheral lymph nodes (PLN), and spleens of EAU
mice treated with (N = 5) or without zebularine (N = 5) on Day 14 post-immunization. (C–F) Summary of two analysis (total of 10 EAU mice treated with zebularine
and 10 without zebularine) of the frequency of IFN-γ+, IL-17+, and Foxp3+ cells in eyes and lymph nodes (each analysis represented the pooled cell population from
5 mice per group). *P < 0.05, paired T test (student T).
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found that zebularine suppressed the expression of Tbx21
(encoding Tbet), but promoted the expression of Foxp3 and Rorc
(encoding RORγt). Suppression of Tbet in Th1 cells correlated
well with the significant reduction of IFN-γ in response to
zebularine treatment. Promotion of Foxp3 expression, which is
consistent with previous reports that other DNA methylation
inhibitors also activate Foxp3 expression in murine models
of asthma, EAE and diabetes (14, 24, 32, 33), explained the
significant alleviation of intraocular inflammation found in
EAU mice. However, upregulation of Rorc expression seemed
contradictory to the reduction of IL-17 expression by zebularine
found both in vitro and in vivo. Although RORγt is the
critical transcription factor promoting IL-17 expression and
Th17 differentiation, other transcription factors such as STAT3,
IRF4, and BATF are also responsible for the coordinated
regulation of IL-17 expression (34). Therefore, the suppression
of IL-17 expression by zebularine may depend on a RORγt
independent pathway.
Our study demonstrates that zebularine restrains IFN-γ and
IL-17 expression and promotes Foxp3 expression in CD4+
T cells and may serve as a candidate therapeutic agent for
autoimmune uveitis. Further study is warranted to elucidate
the molecular mechanisms by which zebularine epigenetically
regulates the expression of these key cytokines and transcription
factors in T cells.
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